Cited by 341Epilepsy research and treatmentGenetics and Neurodevelopmental DisordersPharmacological Effects and Toxicity Studies

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Open access

Han, Zhou, Chen, Chunling, Christiansen, Anne, Ji, Sophina, Lin, Qian, Anumonwo, Charles, Liu, Chante, Leiser, Steven C., Meena, Aznarez, Isabel, Liau, Gene, Isom, Lori L.·2020·Science Translational Medicine

DOI 10.1126/scitranslmed.aaz6100

Open this paper in CoChat — free account Open PDF

Abstract

Antisense oligonucleotide administration reduces seizures and SUDEP incidence in a mouse model of Dravet syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaz6100

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 630
Mortality in Dravet syndrome
Cooper, M. S., McIntosh, A. M., Crompton, D. E., McMahon, J. M., Schneider, A., Farrell, K., Ganesan, V., Gill, D. S., Kivity, S., Lerman‐Sagie, T., et al. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.006 · Cited by 323
Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel
Wirrell, E. C., Laux, L., Donner, E. J., Jetté, N., Knupp, K. G., Meskis, M. A., Miller, I., Sullivan, J. E., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 287
The genetics of Dravet syndrome
Marini, C., Scheffer, I. E., Nabbout, R., Suls, A., Jonghe, P. D., Zara, F., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02997.x · Cited by 276
Incidence of Dravet Syndrome in a US Population
Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248
dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice
Colasante, G., Lignani, G., Brusco, S., Berardino, C. D., Carpenter, J. C., Giannelli, S. G., Valassina, N., Bido, S., Ricci, R., Castoldi, V., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.018 · Cited by 246
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 242
Cannabinoids in treatment-resistant epilepsy: A review
O’Connell, B. K., Gloss, D. S., & Devinsky, O. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.012 · Cited by 228
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
Lim, K., Zhou, H., Jeon, H. Y., Kach, J., Jing, E., Weyn‐Vanhentenryck, S. M., Downs, M., Corrionero, A., Oh, R. S., Scharner, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17093-9 · Cited by 216
Self-citation

Flagged first, then by citations

Show all 30 references

1 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

C. Dravet, M. Bureau, H. Oguni, Y. Fukuyama, O. Cokar, Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv. Neurol. 95, 71–102 (2005).

Sorted by citations

Items 301–340 of 340

Identification of a pathogenic deep intronic variant in ATRX ends a diagnostic odyssey
van der Smagt, J. J., Lampri, A. P., Lange, I., Alders, M. M., Houben, M. L., Koudijs, M. J., & van Jaarsveld, R. H. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104949
Gene Therapy for Refractory Epilepsy
Kullmann, D. M. (2024) · doi:10.1093/med/9780197549469.003.0077
AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet syndrome
Diaz, J. F. A., Chilcott, E. M., Almacellas‐Barbanoj, A., Keegan, A., Gurung, S., Pauzuolyte, V., Waddington, Z., Kyriacou, M., McTague, A., Cross, J. H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102942
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Interneuron FGF13 regulates seizure susceptibility via a sodium channel-independent mechanismPreprint
Lin, S., Gade, A. R., Wang, H., Niemeyer, J. E., Galante, A., DiStefano, I. A., Towers, P., Nunez, J., Matsui, M., Schwartz, T. H., et al. (2024) · eLife · doi:10.7554/elife.98661.2
SCN2A-Related Disorders
Abbott, M., Bender, K. J., Brunklaus, A., Demarest, S., Egan, S. M., Haviland, I., Kearney, J. A., Myers, L. S., Olson, H. E., Sanders, S., et al. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009530361 · Cited by 2
History, mystery, and prospects in SCN1A channelopathies/channelepsies
Chen, S.-J. (2025) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2025.03.001
Prenatal sodium channel dysfunction in Dravet syndrome alters cortical developmentPreprint
Zourray, C., Mills, J., Mills, J. D., Mainardi, M., Street, J., Bartkiewicz, J., Mihaylov, S. R., Sartorelli, J., O’Neill, N., Carpenter, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6566247/v1 · Cited by 1
Molecular genetics of benign adult familial myoclonus epilepsy
Ishiura, H. (2025) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-002111
Two Halves Make a Whole SCN1A
Wong, J. C. (2025) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597251355871
Knockdown-Replace: A New Dynamic for Treatment of Dynamin-1 Related developmental and epileptic encephalopathy (DEE)
Wagnon, J. L. (2025) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597251370432
Utilization of Induced Pluripotent Stem Cell-Derived Neurons to Investigate the Splice-Modification Efficacy of Splice-Switching Drug Candidates
Ueta, Y., Ohara, H., Awaya, T., & Hagiwara, M. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4738-7_12
Molecular messengers of the brain: tRNA-derived small RNAs at the crossroads of brain development and neurodevelopmental disorders
Li, R., Li, X., Wang, H., Chu, H., Dong, M., Zhang, J., Gao, K., Gui, J., & Jiang, Y. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107146
Antisense oligonucleotide of cargo adaptor BICD2 long-term effectively alleviates neuropathic pain via activation of PSD95 in the mouse spinal dorsal horn
Wu, Z., Xu, Y., Xie, J., Ma, G., Li, Y.-X., Yang, T., Liang, J.-H., Li, Y., Wang, Q., Hao, L.-Y., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110793
CRYPTID-exon : streamlined detection of cryptic exons from RNA-seq dataPreprint
Khokhar, E. S., Brokaw, K., Kartje, Z. J., Krykbaeva, M., Calvo-Roitberg, E., Hedger, A. K., Lee, J., Wagh, A. A., Watts, J. K., & Pai, A. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694983
Mapping NMD-coupled alternative splicing in iPSC-derived brain cells: a resource for therapeutic discoveryPreprint
Wijnant, K. N., Schuurmans, I. M. E., Mordelt, A., Wu, K. M., Kwint, M. P., Vissers, L. E. L. M., & Kasri, N. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.19.700316 · Cited by 1
The impact of seizures on REM sleep and the cholinergic pedunculopontine nucleus in a mouse model of Dravet SyndromePreprint
Santiago-Colon, K., Rana, C., Toth, B. A., Kravchenko, J. A., Barden, J., VanHorn, I., Jack, A., Hollier, A., Qureshi, R., Haberland, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.706417
Self-citation
Encephalopathy and Seizures: Consequence, Cause, or Both?
Mack, M., Sogawa, Y., & Asato, M. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-10099-3_24
eSkip2 prioritizes exon-skipping antisense oligonucleotide target regions across exon–intron contextsPreprint
Chiba, S., Kunitake, K., Shirakaki, S., Haque, U. S., Wilton-Clark, H., Shah, M. N. A., Leckie, J., Matsui, K., Uno-Ono, F., Yokota, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.722571
Antisense Oligonucleotides Targeting an LDLR Regulatory RNA Increase LDLR Expression and Reduce LDL-cholesterol in VivoPreprint
Gnanapradeepan, K., Manska, S., Schwartz, B., Golczer, G., Huang, J., Kelkar, R. S., Masteller, A. M., Pilankar, S., Richter, M., Waldron, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729508
At the forefront of gene-based therapies in Dravet syndrome
Riva, A., Gioacchino, S. D., Volpedo, G., Risso, B., Lillo, A. D., Zara, F., Falace, A., & Striano, P. (2026) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2683554
Correction of aberrant splicing caused by intronic CAPN3 pathogenic variants using RNA-targeted therapeutic strategies in limb-girdle muscular dystrophy type R1
Li, G., Guo, Y., Wang, G., Liu, H., Lv, X., & Lin, P. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04451-x
Targeted gene editing of PCCA pseudoexon using CRISPR-Cas12a for potential therapy in propionic acidemia
Álvarez, M., Álamo, J. V. D., Richard, E., & Desviat, L. R. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102990
A Two-Feature Quantitative EEG Index of Pediatric Epilepsy Severity: External Pre-Validation on CHB-MIT and Roadmap to Dravet Cohorts
Uppalapati, K., Yimenicioglu, B., Abdulkareem, S., Uppalapati, B., Kamath, V., Eftekhari, A., & Ayyappan, P. (2025) · International IEEE/EMBS Conference on Neural Engineering · doi:10.1109/ner61569.2025.11588973 · Cited by 2
SafeSense: An open-access safety atlas for antisense oligonucleotides adverse events in human
Vaknin, N., Ziv, A., Chernobylsky, T., Avkin-Nachum, S., Rechavi, G., Dominissini, D., & Mor, N. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103035
Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy
Saravanan, A., Safran, J., Loughman, A., Lin, G., Vaid, S., Allababidi, D., Tessier, P. M., & Dang, L. T. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70500
Epilepsy‐Dyskinesia Syndromes: The Venn Diagram of Genetic Epilepsy and Movement Disorders
Bernardi, K., Alecu, J. E., Achkar, C. M. E., Tochen, L. S., Pearl, P. L., & Ebrahimi‐Fakhari, D. (2026) · Movement Disorders · doi:10.1002/mds.70403
Plötzlicher, unerwarteter Epilepsietod: Neue Erkenntnisse und Wege zur SUDEP-Prävention
Mann, C., & Rosenow, F. (2026) · Deutsches Ärzteblatt · doi:10.3238/persneuro.2026.08.07.01
An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy
Feng, P., Gao, P., Meng, S., Yuan, Y., Krainer, A. R., & Hua, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606494123
Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases
Aartsma-Rus, A. M., de Gusmão, C. M., Demarest, S., van Roon‐Mom, W., Graessner, H., Bush, L. W., Kogel, C., Yu, T. W., Synofzik, M., & Schüle, R. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102989 · Cited by 1
Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification
Martins, W. A. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080830
Nonsense-mediated mRNA decay and associated splicing patterns in neurodevelopmental disorders
Anisimova, P. E., Filat’eva, A. E., Tarabykin, V. S., & Kondakova, E. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1914793
Advancing Disease Modification in Dravet Syndrome
Fine, A. L. (2026) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597261456005
Noncoding RNAs in epilepsy: from molecular mechanisms to clinical translation
Wang, J., Hu, X., Zheng, M., Qin, R., Zhao, W., Jiang, W., & Ma, D. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0098
Genetic Diagnosis in Epilepsy: Implications for Clinical Management
Schatz, K. S., Lammert, D. B., & Habela, C. W. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01514-1
ANTISENSE OLIGONUCLEOTIDE THERAPY FOR DRAVET SYNDROME: A CRITICAL REVIEW OF THE EVIDENCE FOR DISEASE MODIFICATION WITH ZOREVUNERSEN
Żmuda, O., Halot, A., Walo, P., Skórka, N., Tatara, M., Skórka, K., Wydra, K., Jakubiec, J., Szubartowski, M., & Szymczyk, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6603
Adeno‐associated virus ‐mediated restoration of Na V 1.1 in targeted brain regions ameliorates epilepsy in symptomatic Dravet syndrome mice
Mainardi, M., Brusco, S., Giannelli, S. G., Broccoli, V., & Colasante, G. (2026) · Epilepsia · doi:10.1002/epi.70517
Precision Therapeutics for Monogenic Epilepsies: From Molecular Mechanisms to Disease Modification in Developmental and Epileptic Encephalopathies and Neurodevelopmental Disorders with Epilepsy
Perry, M. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207886
Dravet Syndrome Updates: Evolving Insights and Emerging Therapeutics
Fukui, S., & Knupp, K. G. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01533-y
Molecular Mechanisms and Therapeutic Advances in SCN1A-Related Dravet Syndrome
Zhang, N. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103472

Authors: Han, Z., Chen, C., Christiansen, A., Ji, S., Lin, Q., Anumonwo, C., Liu, C., Leiser, S. C., Meena, Aznarez, I., Liau, G., & Isom, L. L.
Affiliations: Stoke Therapeutics Inc., Bedford, MA 01730, USA.
University of Michigan (US)
Stoke Therapeutics, Inc. (United States) (US)
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA.
PsychoGenics Inc., Paramus, NJ 07652, USA.
Corresponding author: Isom, Lori L.
ORCID: Han, Zhou
Chen, Chunling
Lin, Qian
Liu, Chante
Leiser, Steven C.
Aznarez, Isabel
Isom, Lori L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2020-08-26
Volume: 12
Issue: 558
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aaz6100
OpenAlex: W3081439212
Cited by: 341
References: 30
Citations by year: 2026: 47 · 2025: 59 · 2024: 52 · 2023: 57 · 2022: 66 · 2021: 52 · 2020: 8
FWCI: 33.37
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Deep Blue (University of Michigan) (submittedVersion)
Funders: Stoke Therapeutics (N/A)
Topics: Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords: antisense oligonucleotides, Dravet syndrome, SCN1A, sodium channel alpha subunit, seizures, sudden unexpected death in epilepsy, tango, gene-specific therapy, mouse model
MeSH terms: Sudden Unexpected Death in Epilepsy, Animals, Epilepsies, Myoclonic, Mice, Inbred C57BL, Seizures, Incidence, Oligonucleotides, Antisense, Mice, NAV1.1 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks